PT912176E - Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao - Google Patents
Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressaoInfo
- Publication number
- PT912176E PT912176E PT97928260T PT97928260T PT912176E PT 912176 E PT912176 E PT 912176E PT 97928260 T PT97928260 T PT 97928260T PT 97928260 T PT97928260 T PT 97928260T PT 912176 E PT912176 E PT 912176E
- Authority
- PT
- Portugal
- Prior art keywords
- pyridyl
- alcanoic
- immunosuppression
- tumors
- treatment
- Prior art date
Links
- 206010062016 Immunosuppression Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title 1
- -1 pyridyl alkane Chemical class 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19624668A DE19624668A1 (de) | 1996-06-20 | 1996-06-20 | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT912176E true PT912176E (pt) | 2003-01-31 |
Family
ID=7797502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97928260T PT912176E (pt) | 1996-06-20 | 1997-06-20 | Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0912176B1 (index.php) |
| JP (1) | JP2000512652A (index.php) |
| AT (1) | ATE224713T1 (index.php) |
| AU (1) | AU3262497A (index.php) |
| DE (2) | DE19624668A1 (index.php) |
| DK (1) | DK0912176T3 (index.php) |
| ES (1) | ES2181006T3 (index.php) |
| PT (1) | PT912176E (index.php) |
| WO (1) | WO1997048397A1 (index.php) |
| ZA (1) | ZA975443B (index.php) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| JPH10338658A (ja) * | 1997-04-08 | 1998-12-22 | Hoechst Marion Roussel Kk | レチノイド作用調節剤 |
| US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
| DE19756235A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
| DE19756212A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19756261A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
| DE19818044A1 (de) * | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| JP2002522499A (ja) * | 1998-08-12 | 2002-07-23 | スミスクライン・ビーチャム・コーポレイション | カルシウム分解化合物 |
| DE19908483A1 (de) * | 1999-02-26 | 2000-10-05 | Klinge Co Chem Pharm Fab | Inhibitoren der zellulären Niacinamidmononucleotid-Bildung |
| EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| PT1318837E (pt) * | 2000-08-11 | 2004-12-31 | Wyeth Corp | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio |
| IL155093A0 (en) | 2000-09-29 | 2003-10-31 | Glaxo Group Ltd | Morpholin-acetamide derivatives for the treatment on inflammatory diseases |
| EP1348434A1 (en) * | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| EA200701745A1 (ru) * | 2005-03-17 | 2008-06-30 | Пфайзер, Инк. | Циклопропанкарбоксамидные производные |
| PE20071159A1 (es) | 2005-10-31 | 2007-11-30 | Schering Corp | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
| US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| WO2009156421A1 (en) | 2008-06-24 | 2009-12-30 | Topotarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| WO2010023307A1 (en) | 2008-08-29 | 2010-03-04 | Topotarget A/S | Novel urea and thiourea derivatives |
| EP2453883A1 (en) | 2009-07-17 | 2012-05-23 | Topo Target A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| EP2611777B1 (en) | 2010-09-03 | 2016-05-11 | Forma TM, LLC. | N-(4-{[pyridin-3-yl-methyl)carbamoyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer |
| KR20130114119A (ko) | 2010-09-03 | 2013-10-16 | 포르마 티엠, 엘엘씨. | Ｎａｍｐｔ의 억제를 위한 신규 화합물 및 조성물 |
| CN103261160A (zh) | 2010-09-03 | 2013-08-21 | 福马Tm有限责任公司 | 用于抑制nampt的胍化合物和组合物 |
| CN105294549B (zh) * | 2010-09-29 | 2017-12-26 | 英特维特国际股份有限公司 | N‑杂芳基化合物 |
| CA2817093A1 (en) | 2010-11-15 | 2012-05-24 | Abbvie Inc. | Nampt inhibitors |
| BR112013012078A2 (pt) | 2010-11-15 | 2019-09-24 | Abbvie Inc | inibidores de nampt e rock |
| JP5978293B2 (ja) | 2011-05-04 | 2016-08-24 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔを阻害するための新規な化合物および組成物 |
| AR082889A1 (es) | 2011-05-09 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones para la inhibicion de nampt |
| JP2015516436A (ja) | 2012-05-11 | 2015-06-11 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔ阻害薬 |
| CN104583194A (zh) | 2012-05-11 | 2015-04-29 | 艾伯维公司 | 作为nampt抑制剂的哒嗪和吡啶衍生物 |
| JP2015516437A (ja) | 2012-05-11 | 2015-06-11 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔ阻害薬として使用されるチアゾールカルボキサミド誘導体 |
| HK1208221A1 (en) | 2012-05-11 | 2016-02-26 | Abbvie Inc. | Nampt inhibitors |
| US9938258B2 (en) | 2012-11-29 | 2018-04-10 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| EP3016946B1 (en) | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| JP2018528196A (ja) | 2015-08-18 | 2018-09-27 | カリオファーム セラピューティクス，インコーポレイテッド | 癌の治療のための（ｓ，ｅ）−３−（６−アミノピリジン−３−イル）−ｎ−（（５−（４−（３−フルオロ−３−メチルピロリジン−１−カルボニル）フェニル）−７−（４−フルオロフェニル）ベンゾフラン−２−イル）メチル）アクリルアミド |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| SG11201903013SA (en) | 2016-10-18 | 2019-05-30 | Seattle Genetics Inc | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| US11931414B2 (en) | 2017-04-27 | 2024-03-19 | Seagen Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| US20200360531A1 (en) | 2018-01-31 | 2020-11-19 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| CN112312899B (zh) | 2018-05-04 | 2024-11-22 | 治疗方案股份有限公司 | 靶向癌症干细胞的癌症治疗 |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| PH12022551081A1 (en) | 2019-11-06 | 2024-06-19 | Remedy Plan Inc | Cancer treatments targeting cancer stem cells |
| EP4337639A1 (en) | 2021-05-13 | 2024-03-20 | Remedy Plan, Inc. | Nampt inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| JP2832979B2 (ja) * | 1988-02-15 | 1998-12-09 | 武田薬品工業株式会社 | 不飽和カルボン酸アミド誘導体 |
| EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
| WO1991015484A1 (de) * | 1990-04-10 | 1991-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridine als arzneimittel |
| EP0525023A1 (de) * | 1990-04-10 | 1993-02-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridinester |
-
1996
- 1996-06-20 DE DE19624668A patent/DE19624668A1/de not_active Ceased
-
1997
- 1997-06-19 ZA ZA9705443A patent/ZA975443B/xx unknown
- 1997-06-20 JP JP10502317A patent/JP2000512652A/ja not_active Withdrawn
- 1997-06-20 DE DE69715861T patent/DE69715861T2/de not_active Expired - Lifetime
- 1997-06-20 PT PT97928260T patent/PT912176E/pt unknown
- 1997-06-20 EP EP97928260A patent/EP0912176B1/en not_active Expired - Lifetime
- 1997-06-20 WO PCT/EP1997/003244 patent/WO1997048397A1/en not_active Ceased
- 1997-06-20 AU AU32624/97A patent/AU3262497A/en not_active Abandoned
- 1997-06-20 AT AT97928260T patent/ATE224713T1/de active
- 1997-06-20 ES ES97928260T patent/ES2181006T3/es not_active Expired - Lifetime
- 1997-06-20 DK DK97928260T patent/DK0912176T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0912176A1 (en) | 1999-05-06 |
| DK0912176T3 (da) | 2003-01-13 |
| AU3262497A (en) | 1998-01-07 |
| ATE224713T1 (de) | 2002-10-15 |
| DE69715861T2 (de) | 2003-06-12 |
| DE19624668A1 (de) | 1998-02-19 |
| DE69715861D1 (de) | 2002-10-31 |
| JP2000512652A (ja) | 2000-09-26 |
| ZA975443B (en) | 1998-02-10 |
| ES2181006T3 (es) | 2003-02-16 |
| EP0912176B1 (en) | 2002-09-25 |
| WO1997048397A1 (en) | 1997-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT912176E (pt) | Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao | |
| PT923570E (pt) | Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| BR9812371A (pt) | Tratamento de distúrbio de conduta | |
| ATE263157T1 (de) | Nematizide trifluorbutene | |
| BRPI0113286B8 (pt) | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. | |
| CY1107493T1 (el) | Μεθοδοι και συνθεσεις για την προληψη ανεκτικοτητας στα βρογχοδιασταλτικα | |
| FI963070A0 (fi) | Klooripyrimidiinivälituotteita | |
| DK0934309T3 (da) | Nye pyridylalkansyreamider som cytostatiske og immunosuppressive midler | |
| BR9813028A (pt) | Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos | |
| EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| DK0960127T3 (da) | Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf | |
| BR9812357A (pt) | Tratamento de distúbio oposicional desafiador | |
| BR9805544C1 (pt) | Uso de um composto. | |
| BG99177A (bg) | Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза | |
| NZ329807A (en) | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome | |
| ES2053907T3 (es) | Pomada topica. | |
| MX9505192A (es) | Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico. | |
| TR200000697T2 (tr) | İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları. | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| SE9604582D0 (sv) | Novel compounds | |
| DE60015098D1 (de) | 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose | |
| ES2082212T3 (es) | Nuevos inhibidores de alfa-glucosidasa. | |
| ATE248163T1 (de) | Neuartige, pharmazeutisch aktive verbindung | |
| ATE265418T1 (de) | Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine |